CLDF Title
Home | Contact Us | Bookmark
HEPATITIS
HBV HCV HDV
CIRRHOSIS
CIRRHOSIS HEPATIC ENCEPHALOPATHY (HE) HEPATORENAL SYNDROME (HRS) THROMBOCYTOPENIA
NASH
CHOLESTATIC
PRIMARY BILIARY CHOLANGITIS (PBC)
HCC ALCOHOL LIVER DISEASE PEDIATRIC LIVER DISEASE
About CLDF
Board of Trustees Board of Advisors/Faculty CLDF Committees 2022 GI Fellow Board of Advisors
Embassy of Education  
Slide Library Publications Webcasts Abstract Library Committee Members
 
NASH Single Disease Content  
Publications
 
Slide Library
   Released: 2022
test
 
   Released: 2022
test
 
   Released: 2022
test
Pearls and Pitfalls: Update on emerging therapies in NASH
Michael Charlton, MD & Rohit Loomba, MD
97 slides
 
 
   Released: 2021
test
The Puzzle in Hepatorenal Syndrome Management
Hugo E. Vargas, MD
40 slides
 
 
   Released: 2021
test
COVID-19 and Managing Liver Disease
K. Rajender Reddy, M.D.
33 slides
 
 
   Released: 2021
test
Alcohol-Associated Liver Disease
Michael R. Lucey MD
43 slides
 
 
   Released: 2021
test
Chronic Hepatitis B and D: Emerging Concepts and Treatment
Robert G Gish MD, FAASLD, AGAF, FAST
42 slides
 
 
   Released: 2021
test
Management of Refractory Hepatic Encephalopathy
Jasmohan S. Bajaj, MD
41 slides
 
 
   Released: 2021
test
Hepatitis C: Elimination Strategies in the US
David Bernstein, MD, FAASLD, FACG, FACP, AGAF
43 slides
 
 
   Released: 2021
test
Management of Hepatocellular Carcinoma in 2021
Laura Kulik, MD
45 slides
 
 
   Released: 2021
test
Hot Topics In Pediatric Liver Disease
Rohit Kohli, MBBS, MS
35 slides
 
 
   Released: 2021
test
Thrombocytopenia in CLD
Robert S. Brown, Jr., MD, MPH
32 slides
 
 
   Released: 2021
test
Cholestatic Liver Disease: Current Management and Emerging Therapies
Kris V. Kowdley MD
36 slides
 
 
   Released: 2021
test
Emerging Therapies in NASH
Stephen A Harrison, MD, FACP, FAASLD
32 slides
 
 
   Released: 2021
test
Identifying High Risk NASH Patients Using Noninvasive Techniques (NITs)
Mazen Noureddin, MD, MHSc
42 slides
 
 
   Released: 2021
test
Burden of NASH: Why Do We Need to Care?
21 slides
 
 
   Released: 2021
test
NASH Screening and Diagnosis in Primary Care and Endocrinology Practice Settings: The Role of NITs
52 slides
 
 
   Released: 2021
test
NASH Screening and Diagnosis in Specialty Clinics: The Role of Radiologic Modalities, Serum Fibrosis Tests and Algorithm
40 slides
 
 
   Released: 2021
test
Treatment Endpoints: Clinical vs Regulatory Endpoints
39 slides
 
 
   Released: 2021
test
Combination Therapies in NASH: What's Promising?
21 slides
 
 
   Released: 2021
test
Lifestyle Modification and Current Treatment Regimens for NAFLD
29 slides
 
 
   Released: 2021
test
New Targets for Emerging Therapies in NASH
26 slides
 
 
   Released: 2020
test
Imaging as an Outcome and Endpoint for Clinical Trials of NASH
29 slides
 
 
   Released: 2020
test
Clinical Management of NASH: Diet and Nutrition
41 slides
 
 
   Released: 2020
test
The Comprehensive Global Burden and Impact of NASH
32 slides
 
 
   Released: 2020
test
NAFLD and Cardiovascular Disease
43 slides
 
 
   Released: 2020
test
Imaging as an Outcome and Endpoint for Clinical Trials of NASH
29 slides
 
 
   Released: 2020
test
Challenges in Management and Clinical Trials of NASH in Children
26 slides
 
 
   Released: 2020
test
Weight Loss in NASH: Role of Weight Loss Medications and Surgery
17 slides
 
 
   Released: 2020
test
Why NASH and Exercise?
43 slides
 
 
   Released: 2020
test
Is Histologic Fibrosis Assessment an Appropriate Endpoint / Reference Standard for Clinical Trials?
25 slides
 
 
   Released: 2020
test
NASH and Diabetes Linkage: Where do we go from here?
42 slides
 
 
   Released: 2020
test
Serum Biomarkers and Clinical Algorithms in NASH: Utility in Clinical Trials and Clinical Practice
49 slides
 
 
   Released: 2020
test
Best Practices in NASH Management and Current Status of Drug Development
37 slides
 
 
   Released: 2020
test
Imaging as an Outcome and Endpoint for Clinical Trials of NASH
35 slides
 
 
   Released: 2020
test
NASH: Current Approach and When Will New Treatment Options Be Available?
39 slides
 
 
   Released: 2018
Webcast
NASH 2018
61 slides
 
 
   Released: 2016
Webcast
Get Ready for the Global Epidemic of NASH: Evolving Diagnosis and Treatment Strategies
66 slides
 
 
   Released: 2015
Webcast
Best of the Liver Summit: PBC, NAFLD/NASH and HCV
78 slides
 
 
   Released: 2015
Webcast
Hepatology Update: New Developments in PBC, NAFLD & NASH
77 slides
 
 
   Released: 2015
Webcast
THE LIVER SUMMIT
89 slides
 
 
 
 
Recorded Educational Webinar

 
 
 
Find a NASH Clinical Investigator
Audiocasts from the Symposia at UEGW 2016 - Vienna, Austria
Webcast Library
     
New Advances in NASH Diagnostics and Prognostics - Rohit Loomba, MD, MHSc   Educational Webcast
New Advances in NASH Diagnostics and Prognostics - Mazen Noureddin, MD, MHSc   Educational Webcast
Liver Connect 2022   Educational Webcast
NASH Connect 2022   Educational Webcast
Pearls and Pitfalls update on emerging therapies in NASH   Educational Webcast
2021 Liver Connect Conference   Educational Webcast
International NASH Summit   Educational Webcast
Building a Multi-Departmental Fatty Liver Management Program   Educational Webinar
NAFLD - NASH Treatment Outlook   Educational Webinar
Epidemiology and Pathophysiology of NAFLD - NASH   Educational Webinar
Looking Into the Crystal Ball: Predicting the Future Challenges of Fibrotic NASH   Educational Webinar
Implications of NAFLD in People with HIV   Educational Webinar
Implications of the NAFLD Epidemic on the Future of Liver Transplantation   Educational Webinar
Clinical Updates in the Management of Fatty Liver Disease in Patients with Type 2 Diabetes   Educational Webinar
Fatty Liver Disease in Adolescent and Pediatric Patients   Educational Webinar
Abstract Library
1.Comparative effectiveness of medical treatment vs.metabolic surgery for histologically proven non-alcoholic steatohepatitis and fibrosis: a matched network meta-analysis
 

Hepatobiliary Surg Nutr. 2022 Oct;11(5):696-708. doi: 10.21037/hbsn-21-5.

Adrian T Billeter 1, Beatrice Reiners 1, Svenja E Seide 2, Pascal Probst 1 3, Eva Kalkum 3, Christian Rupp 4, Beat P Müller-Stich
 
2.Mechanisms of nonalcoholic steatohepatitis-associated cardiomyopathy: key roles for liver-heart crosstalk
 

Curr Opin Lipidol. 2022 Oct 1;33(5):295-299.doi: 10.1097/MOL.0000000000000845. Epub 2022 Aug 3.

Dolores B Njoku 1 2, Joel D Schilling 2 3, Brian N Finck 4
 
3.Porto-sinusoidal vascular disorder
 

J Hepatol. 2022 Oct;77(4):1124-1135. doi: 10.1016/j.jhep.2022.05.033.Epub 2022 Jun 9.

Andrea De Gottardi 1, Christine Sempoux 2, Annalisa Berzigotti 3
 
4.Role of non-coding RNAs on liver metabolism and NAFLD pathogenesis
 

Hum Mol Genet. 2022 Oct 20;31(R1):R4-R21. doi: 10.1093/hmg/ddac088.

Gene Qian 1, Núria Morral 1 2
 
5.Mitochondrial alterations in fatty liver diseases
 

J Hepatol. 2022 Oct 6;S0168-8278(22)03130-0. doi: 10.1016/j.jhep.2022.09.020.Online ahead of print.

Bernard Fromenty 1, Michael Roden 2
 
6.Gut-liver axis: Pathophysiological concepts and clinical implications
 

Cell Metab. 2022 Nov 1;34(11):1700-1718. doi: 10.1016/j.cmet.2022.09.017.Epub 2022 Oct 7.

Herbert Tilg 1, Timon E Adolph 2, Michael Trauner 3
 
7.GCKIII kinases in lipotoxicity: Roles in NAFLD and beyond
 

Hepatol Commun. 2022 Oct;6(10):2613-2622. doi: 10.1002/hep4.2013.Epub 2022 May 31.

Margit Mahlapuu 1, Mara Caputo 1, Ying Xia 1, Emmelie Cansby 1
 
8.The role of oxidized lipid species in insulin resistance and NASH in children
 

Front Endocrinol (Lausanne). 2022 Oct 3;13:1019204.doi: 10.3389/fendo.2022.1019204. eCollection 2022.

Nicola Santoro 1 2 3, Ariel E Feldstein 4
 
9.The Emerging Role of Extracellular Vesicles and Autophagy Machinery in NASH-Future Horizons in NASH Management
 

Int J Mol Sci. 2022 Oct 12;23(20):12185. doi: 10.3390/ijms232012185.

Eleni-Myrto Trifylli 1 2, Anastasios G Kriebardis 1, Evangelos Koustas 2, Nikolaos Papadopoulos 2, Melanie Deutsch 3, Georgios Aloizos 2, Sotirios P Fortis 1, Effie G Papageorgiou 1, Ariadne Tsagarakis 4, Spilios Manolakopoulos 3
 
10.HCC Surveillance in NAFLD patients
 

Semin Liver Dis. 2022 Oct 10. doi: 10.1055/a-1957-8540. Online ahead of print.

George Cholankeril 1, Hashem El-Serag 1
 
11.HCC Surveillance in NAFLD patients
 

Semin Liver Dis. 2022 Oct 10. doi: 10.1055/a-1957-8540. Online ahead of print.

George Cholankeril 1, Hashem El-Serag 1
 
12.A Review of Defatting Strategies for Non-Alcoholic Fatty Liver Disease
 

Int J Mol Sci. 2022 Oct 5;23(19):11805. doi: 10.3390/ijms231911805.

Erin Nicole Young 1, Murat Dogan 1, Christine Watkins 1, Amandeep Bajwa 1, James D Eason 1, Canan Kuscu 1, Cem Kuscu 1
 
13.Incidence and Impact of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients with Adenocarcinoma of the Esophagus Treated with Curative Intent
 

World J Surg. 2022 Oct 20. doi: 10.1007/s00268-022-06781-w. Online ahead of print.

John V Reynolds 1, Noel E Donlon 2, Jessie A Elliott 2, Brendan Moran 2, Hugo Temperley 2, Tim S Nugent 2, Maria Davern 2, Sinead King 2, Melissa Conroy 2, Joanne Lysaght 2, Narayanasamy Ravi 2, Carmel Ryan 3, Stephen Finn 3, Suzanne Norris 4, Clare L Donohoe 2
 
14.Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles
 

Hepatology. 2022 Oct;76(4):1121-1134. doi: 10.1002/hep.32427. Epub 2022 Mar 17.

Ibon Martínez-Arranz 1, Chiara Bruzzone 2, Mazen Noureddin 3, Ruben Gil-Redondo 2, Itziar Mincholé 1, Maider Bizkarguenaga 2, Enara Arretxe 1, Marta Iruarrizaga-Lejarreta 1, David Fernández-Ramos 2, Fernando Lopitz-Otsoa 2, Rebeca Mayo 1, Nieves Embade 2, Elizabeth Newberry 4, Bettina Mittendorf 5, Laura Izquierdo-Sánchez 6, Vaclav Smid 7, Jorge Arnold 8, Paula Iruzubieta 9, Ylenia Pérez Castaño 10, Marcin Krawczyk 11 12, Urko M Marigorta 2, Martine C Morrison 13, Robert Kleemann 13, Antonio Martín-Duce 14, Liat Hayardeny 15, Libor Vitek 7, Radan Bruha 7, Rocío Aller de la Fuente 16, Javier Crespo 9, Manuel Romero-Gomez 17, Jesus M Banales 6 18, Marco Arrese 8 19, Kenneth Cusi 20, Elisabetta Bugianesi 21, Samuel Klein 5, Shelly C Lu 3, Quentin M Anstee 22 23, Oscar Millet 2, Nicholas O Davidson 4, Cristina Alonso 1, José M Mato 2
 
15.Review: Vascular effects of PPARs in the context of NASH
 

Aliment Pharmacol Ther. 2022 Jun 5. doi: 10.1111/apt.17046. Online ahead of print.

Sergi Guixé-Muntet 1, Louise Biquard 2, Gyongyi Szabo 3, Jean-François Dufour 4, Frank Tacke 5, Sven Francque 6 7, Pierre-Emmanuel Rautou 8, Jordi Gracia-Sancho 1 4
 
16.Treating inflammation to combat non-alcoholic fatty liver disease
 

J Endocrinol. 2022 Oct 1;JOE-22-0194. doi: 10.1530/JOE-22-0194.Online ahead of print.

Leke Wiering 1, Frank Tacke 2
 
17.A critical evaluation of the role of iron overload in fatty liver disease
 

J Gastroenterol Hepatol. 2022 Oct;37(10):1873-1883. doi: 10.1111/jgh.15971.Epub 2022 Aug 16.

Monique Fernandez 1, Julie Lokan 2, Christopher Leung 1 3, Andrew Grigg 1 4
 
18."Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV"
 

HIV Med. 2022 Sep;23(8):911-921. doi: 10.1111/hiv.13274. Epub 2022 Feb 24.

Adriana Cervo 1, Giada Sebastiani 2, Jovana Milic 3 4, Thomas Krahn 2, Sergio Mazzola 5, Salvatore Petta 6, Antonio Cascio 1, Giovanni Guaraldi 3 7, Giovanni Mazzola 1
 
19.Review of existing evidence demonstrates that methotrexate does not cause liver fibrosis
 

J Investig Med. 2022 Oct;70(7):1452-1460. doi: 10.1136/jim-2021-002206.Epub 2022 Aug 24.

Hira Imad Cheema 1, Dirk Haselow 1, Jonathan Ankin Dranoff 2 3
 
20.Linking nutrient sensing, mitochondrial function, and PRR immune cell signaling in liver disease
 

Trends Immunol. 2022 Oct 1;S1471-4906(22)00183-1. doi: 10.1016/j.it.2022.09.002.Online ahead of print.

Claudia Kemper 1, Michael N Sack 2
 
21.NASH and hepatocellular carcinoma: immunology and immunotherapy
 

Clin Cancer Res. 2022 Sep 27;CCR-21-1258. doi: 10.1158/1078-0432.CCR-21-1258.Online ahead of print.

Matthias Pinter 1, David J Pinato 2, Pierluigi Ramadori 3, Mathias Heikenwalder 3
 
22.The epidemiology of non-alcoholic steatohepatitis (NASH) in the United States between 2010-2020: a population-based study
 

Ann Hepatol. 2022 Sep-Oct;27(5):100727. doi: 10.1016/j.aohep.2022.100727. Epub 2022 Jun 11.

Osama Hamid 1, Ahmed Eltelbany 2, Abdul Mohammed 2, Khaled Alsabbagh Alchirazi 2, Sushrut Trakroo 2, Imad Asaad 3
 
23.Mechanotransduction in the pathogenesis of non-alcoholic fatty liver disease
 

J Hepatol. 2022 Sep 5;S0168-8278(22)03059-8. doi: 10.1016/j.jhep.2022.08.028.Online ahead of print.

Emilie K Mitten 1, György Baffy 2
 
24.Non-invasive diagnosis and staging of non-alcoholic fatty liver disease
 

Hormones (Athens). 2022 Sep;21(3):349-368. doi: 10.1007/s42000-022-00377-8.Epub 2022 Jun 4.

Stergios Kechagias 1 2, Mattias Ekstedt 3 4, Christian Simonsson 5 6, Patrik Nasr 3 4
 
25. Exercise during weight loss improves hepatic mitophagy
 

Sports Med Health Sci. 2022 Apr 12;4(3):183-189. doi: 10.1016/j.smhs.2022.04.003.eCollection 2022 Sep.

Megan E Rosa-Caldwell 1 2, Kaylee E Poole 3, Andrew Seija 3, Matthew P Harris 3, Nicholas P Greene 1, Joshua S Wooten 3
 
View More
 
 

HEPATITIS

HBV
HCV
HDV

CIRRHOSIS

Cirrhosis
HE
HRS
Thrombocytopenia

NASH

Webcasts
Slide Library
Abstract Library

CHOLESTATIC

PBC

HCC

Slide Library
Abstract Library

ALCOHOL LIVER DISEASE

Recorded Educational Webinar

PEDIATRIC LIVER DISEASE

Webcasts
Slide Library
Abstract Library

About CLDF

Mission Statement
Board of Trustees
Embassy of Education
Board of Advisors/Faculty
2022 GI Fellow Board of Advisors

Other Resources

Journal Abstracts
Hep C Link to Care

Subscribe

Be the first to know about our latest upcoming programs and events!
CLDF

Follow us
Facebook
Twitter
Youtube
LiverQ
The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2022 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.